Drug Trial News

RSS

Assessing the safety of inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents

New clinical trial data, recently published in The Lancet’s Infectious Diseases, presents an initial report on the effect of an inactivated SARS-CoV-2 vaccine, CoronaVac, on children and adolescents from ages 3-17 in a double-blind, randomized setting.

30 Jun 2021

Clinical trial demonstrates safety of new approach to treat invasive kidney cancer

A new approach using precisely targeted, high-dose radiation to treat invasive kidney cancer proves safe, based on a clinical trial by the UT Southwestern Harold C. Simmons Comprehensive Cancer Center's kidney cancer program. The study, published in the International Journal of Radiation Oncology*Biology*Physics, could offer new hope for patients with a historically dismal condition.

29 Jun 2021

Preliminary results of AAV-mediated gene therapy for Crigler Najjar syndrome

Preliminary results from the European gene therapy trial for Crigler-Najjar syndrome, conducted by Genethon in collaboration with European network CureCN, were presented at the EASL (European Association for the Study of the Liver) annual International Liver Congress on June 26.

28 Jun 2021

An oral pill for COVID-19? Molnupiravir shows promise

Recently, researchers reported molnupiravir as the first oral and direct-acting antiviral that is highly effective at reducing SARS-CoV-2 levels.

27 Jun 2021

Oxford study sheds light on level of antibodies needed to protect against COVID-19 symptoms

Researchers in the UK have reported on the relationship between humoral (antibody) responses and protection against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) following immunization with AstraZeneca’s ChAdOx1 vaccine.

27 Jun 2021

Multisystem Inflammatory Syndrome in Children significantly affects more Black and Latino children

Multisystem Inflammatory Syndrome in Children (MIS-C) significantly affected more Black and Latino children than white children, with Black children at the highest risk, according to a new observational study of 124 pediatric patients treated at Children's National Hospital in Washington, D.C.

25 Jun 2021

FDA issues draft guidance encouraging rational expanded patient eligibility for oncology clinical trials

Today, the FDA issued a draft guidance encouraging industry to include patients with incurable cancers (when there is no potential for cure or for prolonged/near normal survival) in cancer clinical trials, regardless of whether they have received existing alternative treatment options.

24 Jun 2021

Researchers reanalyze COVID RECOVERY trial data on tocilizumab

A Bayesian analysis of the RECOVERY trial suggests the immunosuppressive drug tocilizumab can reduce deaths in hospitalized COVID-19 patients taking corticosteroids as well as patients on oxygen or non-invasive ventilation and likely increases hospital discharge rates. However, it is not clear if patients on invasive ventilation also benefit.

24 Jun 2021

Bivalent DNA SARS-CoV-2 vaccine induces strong humoral and cellular immunity in mice

A team of UK-based scientists has developed and validated a DNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that encodes both spike receptor-binding domain (RBD) and nucleocapsid of the virus as vaccine immunogens.

24 Jun 2021

Study finds no evidence for remdesivir's benefit in severe COVID-19 patients

A new analysis of current data indicates that remdesivir does not show efficacy in regulating the severity of the illness.

23 Jun 2021

Study involving virtual patients is as effective as traditional clinical trials

A study involving virtual rather than real patients was as effective as traditional clinical trials in evaluating a medical device used to treat brain aneurysms, according to new research.

23 Jun 2021

New study enrolls young adults to evaluate SARS-CoV-2 infection

The Prevent COVID U study, which launched in late March 2021 to evaluate SARS-CoV-2 infection and transmission among university students vaccinated with the Moderna COVID-19 Vaccine, has expanded beyond the university setting to enroll young adults ages 18 through 29 years and will now also include people in this age group who choose not to receive a vaccine.

23 Jun 2021

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced presentation of the positive Phase 2 safety and efficacy data for oral opaganib (Yeliva®, ABC294640) in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum (WMF) 2021 (poster #: 5574).

21 Jun 2021

Investigational Alzheimer's drug reduces molecular markers of the disease

An investigational Alzheimer's drug reduced molecular markers of disease and curbed neurodegeneration in the brain, without demonstrating evidence of cognitive benefit, in a phase 2/3 clinical trial led by researchers at Washington University School of Medicine in St. Louis through its Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU).

21 Jun 2021

Combination of doxycycline and TB drug treatment reduces the size of lung cavities

Globally, an estimated 10 million people develop tuberculosis (TB) each year and the disease remains a leading cause of death from a single infectious agent. Standard short-course anti-TB treatment still requires a regimen of at least six months of antimicrobial drugs, and drug-resistant TB is an increasing public health threat.

21 Jun 2021

Common blood pressure drug not effective in reducing hospitalization for mildly-ill COVID-19 outpatients

University of Minnesota Medical School researchers determined that the common blood pressure medication, losartan, is not effective in reducing hospitalization for mildly-ill COVID-19 outpatients.

18 Jun 2021

KIYATEC’s test results accurately predict treatment response in recurrent high-grade glioma patients

KIYATEC, Inc. announced today the publication of new peer-reviewed data that establishes clinically meaningful prediction of patient-specific responses to standard of care therapy, prior to treatment, in newly diagnosed glioblastoma (GBM) and other high-grade glioma (HGG) patients.

18 Jun 2021

Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit

Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary.

18 Jun 2021

Adding immune oncology drug to chemotherapy improves response in subset of breast cancer patients

In a new study by researchers at Yale Cancer Center, combining the immunotherapy drug durvalumab and PARP-inhibitor olaparib with chemotherapy improved response to treatment for women with high-risk, HER2-negative breast cancer, including a subset of estrogen receptor positive cancers.

18 Jun 2021

Regeneron mAb cocktail benefits hospitalized patients with no natural SARS-CoV-2 antibody response

Researchers reporting on findings from the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial in the UK are recommending that any therapeutic use of REGEN-COV may be best restricted to individuals without detectable antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Jun 2021

Previous
1
...
48
49
50
51
52
53
54
...
1143
Next

Drug Trial News

Assessing the safety of inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents

Clinical trial demonstrates safety of new approach to treat invasive kidney cancer

Preliminary results of AAV-mediated gene therapy for Crigler Najjar syndrome

An oral pill for COVID-19? Molnupiravir shows promise

Oxford study sheds light on level of antibodies needed to protect against COVID-19 symptoms

Multisystem Inflammatory Syndrome in Children significantly affects more Black and Latino children

FDA issues draft guidance encouraging rational expanded patient eligibility for oncology clinical trials

Researchers reanalyze COVID RECOVERY trial data on tocilizumab

Bivalent DNA SARS-CoV-2 vaccine induces strong humoral and cellular immunity in mice

Study finds no evidence for remdesivir's benefit in severe COVID-19 patients

Study involving virtual patients is as effective as traditional clinical trials

New study enrolls young adults to evaluate SARS-CoV-2 infection

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

Investigational Alzheimer's drug reduces molecular markers of the disease

Combination of doxycycline and TB drug treatment reduces the size of lung cavities

Common blood pressure drug not effective in reducing hospitalization for mildly-ill COVID-19 outpatients

KIYATEC’s test results accurately predict treatment response in recurrent high-grade glioma patients

Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit

Adding immune oncology drug to chemotherapy improves response in subset of breast cancer patients

Regeneron mAb cocktail benefits hospitalized patients with no natural SARS-CoV-2 antibody response

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News